timothy sykes logo
TEM Stock Jumps As Tempus AI Joins Profitable AI Health Elite Thumbnail
G Google News

TEM Stock Jumps As Tempus AI Joins Profitable AI Health Elite

ELLIS HOBBS•UPDATED SEP. 17, 2026, 12:32 PM ET
Reviewed by Jack Kelloggand Fact-checked by Tim Sykes

Tempus AI Inc. stocks have been trading up by 14.38 percent amid upbeat sentiment on its expanding healthcare AI capabilities.

Key Takeaways

  • Q2 2026 saw Tempus AI (TEM) grow revenue 22% to $382.5M, with a clean swing to positive net income and EBITDA.
  • Strong oncology testing and fast-growing Data and Applications revenue validate Tempus AI’s precision-medicine, data-licensing model.
  • TEM agreed to acquire Personalis for $16.25 per share in a ~$1.5B enterprise-value deal to deepen its AI-driven drug discovery reach.
  • A routine shareholder fairness probe around the Personalis sale adds timing and execution risk that short-term TEM traders must track closely.

Candlestick Chart

Live Update At 12:32:03 EDT: On Thursday, September 17, 2026 Tempus AI Inc. stock [NASDAQ: TEM] is trending up by 14.38%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Tempus AI, trading under ticker TEM, is acting like a name that has finally earned its momentum. The latest Q2 2026 report shows revenue of $382.5M, up 22% year over year. For a high-growth AI healthcare platform, that kind of double‑digit top-line climb matters, but the real shift is below the revenue line.

TEM moved to positive net income of about $5.6M and posted positive EBITDA of roughly $45M, after years of heavy spending. Gross margin sits near 73.5%, signaling strong pricing power and a high-value data and diagnostics mix. At the same time, operating income is still negative, so the path to steady profitability is not smooth yet.

On the balance sheet, Tempus AI shows about $816M in cash and short-term investments and a current ratio above 3, giving TEM room to fund growth and the planned Personalis acquisition. Leverage is noticeable, with long-term debt around $1.36B and return on equity still deeply negative, which tells traders this is a high‑beta, execution-driven story, not a sleepy value play.

More Breaking News

On the chart, TEM has ripped from a recent close near $62 to about $80, a powerful multi-day uptrend backed by expanding ranges and active intraday trading.

Why Traders Are Watching TEM’s Momentum

Tempus AI is finally behaving like the scaled AI-healthcare platform its story has promised. TEM’s 22% revenue jump to $382.5M in Q2 2026, paired with a swing to positive net income and EBITDA, sends a clear message: this is no longer just a “grow at any cost” data science experiment. It is turning into a real business with leverage in the model.

The core driver is Tempus AI’s oncology franchise. Testing volume stayed strong, which matters because that diagnostic flow feeds the company’s multimodal dataset — clinical, molecular, and outcome data tied together. TEM then monetizes that data again through its Data and Applications business, licensing insights and tools to pharma and biotech. That second leg posted robust growth in Q2, confirming that “context is the asset” is more than a marketing line.

Traders love this kind of structure. Diagnostics bring recurring volume and cash flow. Data and applications add higher-margin, scalable revenue. Together they justify richer price-to-sales and price-to-book multiples, which TEM already enjoys.

The price action backs up the story. Over the last several sessions, TEM climbed from the low $60s to over $80, with big intraday ranges and consistent bids on dips. The 5‑minute tape shows early morning demand stepping in around $72–$74, then pushing TEM through $80 with only brief consolidations. That’s classic momentum behavior: higher highs, higher lows, and active dip buying from short-term traders. If revenue growth stays above 20% and profitability keeps improving, many will continue to treat pullbacks in TEM as trading opportunities, not warning signs.

Conclusion

For active traders, Tempus AI is now a textbook momentum‑plus‑fundamentals setup. TEM just proved it can grow revenue at 22% while flipping to positive net income and EBITDA, powered by a 73.5% gross margin business that blends precision diagnostics with high-value data licensing. The oncology engine is humming, and the Data and Applications segment is scaling, giving Tempus AI multiple ways to keep driving top-line expansion.

The planned ~$1.5B Personalis acquisition raises the stakes. At $16.25 per share, Tempus AI is making a big bet that integrating Personalis will deepen its role in AI-driven drug discovery and development. For TEM traders, that means watching how the deal is financed, what it does to leverage, and whether synergy promises show up in future quarters. The shareholder fairness investigation on the seller’s side is typical in M&A, but it still adds a headline risk layer around deal timing that short-term traders cannot ignore.

In this type of name, discipline matters more than opinions. As Tim Sykes likes to hammer home, “Cut losses quickly and don’t fall in love with any stock — patterns and price action always matter more than your beliefs.” As millionaire penny stock trader and teacher Tim Sykes says, “It’s not about how much money you make; it’s about how much money you keep.” For TEM, those patterns are bullish right now. But smart traders in Tempus AI will keep one eye on the chart and the other on the earnings and integration story, treating every move as a trading setup, not a promise. This analysis is for educational and research purposes only, not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”